S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
UN body mulls deep sea mining amid demand for minerals
This Tech Stock Could be the Next Amazon (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
UN food chief: Billions needed to avert unrest, starvation
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
UN body mulls deep sea mining amid demand for minerals
This Tech Stock Could be the Next Amazon (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
UN food chief: Billions needed to avert unrest, starvation
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
UN body mulls deep sea mining amid demand for minerals
This Tech Stock Could be the Next Amazon (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
UN food chief: Billions needed to avert unrest, starvation
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
UN body mulls deep sea mining amid demand for minerals
This Tech Stock Could be the Next Amazon (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
UN food chief: Billions needed to avert unrest, starvation
NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$54.15
-1.90 (-3.39%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$53.26
$56.20
50-Day Range
$43.80
$56.99
52-Week Range
$42.01
$66.00
Volume
1.58 million shs
Average Volume
858,297 shs
Market Capitalization
$5.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.92

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
32.8% Upside
$71.92 Price Target
Short Interest
Healthy
2.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
-0.01mentions of Intra-Cellular Therapies in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$12.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.43) to ($1.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

42nd out of 1,004 stocks

Pharmaceutical Preparations Industry

10th out of 489 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $63.00
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Why Intra-Cellular Therapies Climbed Tuesday
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
3/01/2023
Today
4/01/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.92
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+32.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-256,260,000.00
Net Margins
-102.37%
Pretax Margin
-102.37%

Debt

Sales & Book Value

Annual Sales
$250.31 million
Book Value
$6.93 per share

Miscellaneous

Free Float
91,755,000
Market Cap
$5.16 billion
Optionable
Optionable
Beta
1.13

Key Executives

  • Sharon MatesSharon Mates
    Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline
    Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis
    Chief Scientific Officer & Senior Vice President
  • Suresh DurgamSuresh Durgam
    Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy
    Chief Compliance Officer & Senior Vice President













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

11 equities research analysts have issued twelve-month price objectives for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they expect the company's share price to reach $71.92 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of the year. Since then, ITCI shares have increased by 2.3% and is now trading at $54.15.
View the best growth stocks for 2023 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 2,610,000 shares, a decrease of 21.1% from the February 28th total of 3,310,000 shares. Based on an average daily volume of 672,700 shares, the days-to-cover ratio is currently 3.9 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $87.87 million during the quarter, compared to analyst estimates of $86.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 35.88% and a negative net margin of 102.37%. The company's revenue for the quarter was up 242.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.05) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $54.15.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 4/1/2023 by MarketBeat.com Staff